Please assess the completion status of the following clinical trial:

Trial Title: Treatment With hOKT3gamma1(Ala-Ala) in T1DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with T1DM within the past 6 weeks~* have a body weight ≥26 kg at the time of enrollment~* have detectable anti-GAD, anti-ICA512/IA-2, or insulin autoantibodies (if the participant has been on insulin ≤10 days).~Exclusion Criteria:~* Pregnant or lactating females;~* Prior OKT3 treatment;~* Known hypersensitivity to murine products;~* Uncompensated heart failure or fluid overload, recent myocardial infarction;~* History of epilepsy, cancer, active infection, atopic disease, active Grave's disease, cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular disease, cerebrovascular disease, any concurrent autoimmune diseases, asthma;~* Any medical condition that in the opinion of the investigator will interfere with safe completion of the trial;~* Inability to give informed consent;~* Prior participation in a clinical trial that could potentially affect diabetes or immunologic status;~* Participation in a clinical trial within the last 6 weeks;~* HIV positive;~* Positive for Hepatitis B surface antigen or Anti-Hepatitis C antibody;~* Seropositivity for Toxoplasmosis (IgG);~* Lymphopenia (\<1000 lymphocytes/microliter);~* Thrombocytopenia (\<150,000/mm3 platelets);~* Anemia (Hgb \< 10g/dL);~* Vaccination with a live virus within the past 6 weeks;~* Positive PPD skin test;~* Any infectious mononucleosis-like illness within the 3 months prior to enrollment;~* Serologic evidence of acute infection with EBV or CMV based on tests listed and as defined by the protocol.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).